Whether Momelotinib can treat myelofibrosis and its efficacy evaluation

Momelotinib (Momelotinib) is an oral Janus kinase (JAK) inhibitor that mainly targets JAK1 , JAK2 and ACVR1 pathways are used to treat myelofibrosis (Myelofibrosis, MF) and other myeloproliferative tumors. The drug inhibits the abnormal JAK-STAT signaling pathway, thereby reducing the release of inflammatory factors, improving hematopoietic function, reducing spleen volume, and alleviating disease-related symptoms. Myelofibrosis is a disease characterized by bone marrow scarring, hematopoietic abnormalities and anemia. The emergence of molotinib provides patients with a new treatment option, especially for patients with anemia. It has significant advantages.

From a clinical efficacy perspective, molotinib has shown good results in a number of international Phase III clinical trials (such as the MOMENTUM study). Research results show that molotinib can not only significantly reduce the size of the spleen (SPV50response rate reaches 25%～30%), but also performs well in improving systemic symptoms related to myelofibrosis. In addition, compared with the commonly used drug Ruxolitinib (Ruxolitinib), an outstanding advantage of molotinib is that it can simultaneously improve the anemia problem. Studies have shown that patients who received molotinib showed a significant increase in hemoglobin levels after 12 to 24 weeks, and some patients no longer even needed blood transfusion support.

The mechanism by which molotinib improves anemia is related to its uniqueACVR1 inhibition. ACVR1 is one of the important pathways that regulate iron metabolism and erythropoiesis. By inhibiting this pathway, molotinib can reduce the level of hepcidin (Hepcidin), thereby promoting iron utilization and erythropoiesis. This feature gives molotinib a clinical advantage in the treatment of myelofibrosis patients with symptoms of anemia. Compared with other JAK inhibitors, it not only controls disease progression, but also improves patients' quality of life and physical condition. Therefore, it has been approved by the US FDA in 2023 for the treatment of moderate to severe myelofibrosis.

In general, molotinib is an innovative drug in the current field of myelofibrosis treatment that has the triple functions of "anti-splenomegaly, controlling symptoms, and promoting hematopoiesis". For patients with significant anemia, repeated transfusion requirements, or resistance to ruxolitinib, molotinib offers new therapeutic hope. However, it is still necessary to monitor potential side effects during use, such as mild diarrhea, headache, decreased platelets, and abnormal liver function indicators. In the future, with the accumulation of more real-world research data, molotinib is expected to become an important part of personalized treatment of myelofibrosis, bringing patients longer survival and better quality of life.

Reference materials:https://www.drugs.com/